Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NRA5990043 | Other Identifier | Alias Study Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Aromasin® (Exemestane) was approved in China for adjuvant treatment of postmenopausal women with estrogen receptor (ER) positive early invasive breast cancer who have received 2-3 years of tamoxifen & are switched to Aromasin® for completion of a total of 5 consecutive years of adjuvant hormonal therapy by State Food and Drug Administration (SFDA) with clinical trial waive. While Aromasin® has been used in China for adjuvant therapy of breast cancer since then, there is currently lack of systematic collection and analysis for the efficacy and safety data of Aromasin® adjuvant setting in Chinese population. The Aromasin® Interventional Study is being proposed to collect data systematically and to assess the efficacy and safety of Aromasin® adjuvant setting in Chinese population.
This is interventional study and single arm study. N/A
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Aromasin (exemestane) | Drug | the dosage, frequency and duration base on the LPD approved by SFDA. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Time-to-Event | An event was defined as the earliest occurrence of any of the following: 1) Loco-regional/distant recurrence of the primary breast cancer (BC) (Loco-regional recurrence was defined as any recurrence in the ipsilateral breast, chest wall or axillary lymph nodes.); 2) Appearance of a second primary or contralateral breast cancer; 3) Death due to any cause. | 2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years) |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants Experiencing Each Event | An event was defined as the following: 1) Loco-regional/distant recurrence of the primary breast cancer (Loco-regional recurrence was defined as any recurrence in the ipsilateral breast, chest wall or axillary lymph nodes.); 2) Appearance of a second primary or contralateral breast cancer; 3) Death due to any cause. | 2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
The patient must be postmenopausal woman.
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The First Affiliated Hospital of Bengbu Medical College/Medical Oncology Department | Bengbu | Anhui | 233004 | China | ||
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Not provided
Not provided
Not provided
A total of 564 participants were assigned into the study and 558 participants received the study treatment. (6 participants were withdrawn from the study prior to the first dose of Aromasin.)
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Exemestane | Participants received exemestane (Aromasin) tablet 25 mg once daily in this study. They had previously taken tamoxifen for 2 to 3 years and switched to Aromisin in this study for completion of 5 consecutive years of adjuvant hormonal therapy. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Jun 29, 2016 | Nov 26, 2019 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Incidence Rate of Each Event | Incidence rate (per annum) of the event was defined as a ratio of the number of events and the total exposure time (in years) to Aromasin therapy. | 2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years) |
| Hazard Ratio: the Relationship Between (Human Epidermal Growth Factor Receptor 2) HER2 Status and Time-to-Event | A Cox proportional hazards regression model was used to evaluate the relationship between HER2 status level (binary) and time-to-event (Positive vs Negative). The method for selecting factors for the Cox regression model was based on significant results at univariate analysis and the clinical judgement for the multivariate model. Stepwise method was used for the selection of final independent variables. The criteria for stepwise selection were pentry = 0.25 and pstay = 0.15. | 2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years) |
| Harzard Ratio: the Relationship Between Multiple Disease Variables and Time-to-Event | A Cox proportional hazards regression model with stepwise selection was used to evaluate the influence of multiple disease variables on the time-to-event. The disease variables in the initial model included Eastern Cooperative Oncology Group [ECOG] performance status at diagnosis; and Tumor, Lymph Node and Metastasis [TNM] stage at initial diagnosis. The ECOG Performance Status describes a patient's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability. ECOG performance status at diagnosis level included 0, 1, 2, 3 and 4, with Level 0 as the best status and Level 4 as the worst. The TNM system helps describe the size of cancer tumor and the extent to which it spreads to nearby tissues/distant parts of the body. TNM stage at initial diagnosis level included 1 (Stage I), 2 (Stage IIA), 3 (Stage IIB), 4 (Stage IIIA), 5 (Stage IIIB) and 6 (Stage IIIC), with Level 1 as the best status and Level 6 as the worst. | 2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years) |
| Number of Participants With Discontinuation Due to Adverse Events (AEs) | Participants permanently discontinued from the study due to AEs were counted for this outcome measure. An AE is any untoward medical occurrence in a clinical investigation subject administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. The number of participants with discontinuation due to all-causality and treatment-related AEs are reported below. Treatment-related AEs were determined by the investigator. | 2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years) |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | All-causality TEAEs were counted for this outcome measure. TEAE is defined as an event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state. The number of participants with all-causality and treatment-related TEAEs are reported below. Treatment-related TEAEs were determined by the investigator. | 2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years) |
| The First Affiliated Hospital of Anhui Medical University |
| Hefei |
| Anhui |
| 230022 |
| China |
| Second Affiliated hospital of Anhui Medical University | Hefei | Anhui | 230601 | China |
| The First Affiliated Hospital of Chongqing Medical University | Chongqing | Chongqing Municipality | 400016 | China |
| The First hospital of LanZhou university | Lanzhou | Gansu | 730000 | China |
| Breast Surgery of The Second Affiliated Hospital of Guangzhou Medical University | Guangzhou | Guangdong | 510260 | China |
| SUN YAT-SEN Memorial Hospital , SUN YAT-SEN University | Guangzhou | Guangdong | 510260 | China |
| Cancer Hospital of Shantou University Medical College | Shantou | Guangdong | 515041 | China |
| Thyroid and breast surgery | Shenzhen | Guangdong | 518035 | China |
| Affiliated hospital of Guangdong medical college | Zhanjiang | Guangdong | 524001 | China |
| Hainan General Hospital | Haikou | Hainan | 570311 | China |
| Fourth Hospital of Hebei Medical University | Shijiazhuang | Hebei | 050011 | China |
| Harbin Medical University Cancer Hospital | Harbin | Heilongjiang | 150081 | China |
| The First Affiliated Hospital of Xinxiang Medical University | Weihui | Henan | 453100 | China |
| Henan Cancer Hospital | Zhengzhou | Henan | 450000 | China |
| Henan provincial people's hospital | Zhengzhou | Henan | 450000 | China |
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou | Henan | 450000 | China |
| Jingzhou Hospital Tongji Medical College Huazhong university of science and Technology | Jingzhou | Hubei | 434020 | China |
| Breast and thyroid surgery of the Central Hospital of WuHan | Wuhan | Hubei | 430014 | China |
| Hunan Provincial People's Hospital | Changsha | Hunan | 410005 | China |
| Xiangya Hospital Central South University /Department of Breast | Changsha | Hunan | 410008 | China |
| The Affiliated Hospital of inner Mongolia medical university | Hohhot | Inner Mongolia | 010021 | China |
| Changzhou No.2 People's Hospital | Changzhou | Jiangsu | 213004 | China |
| Jiangsu Cancer Hospital/ Surgery Department | Nanjing | Jiangsu | 210000 | China |
| Jinling Hospital | Nanjing | Jiangsu | 210002 | China |
| Jiangsu Province Hospital/ Surgery Department | Nanjing | Jiangsu | 210029 | China |
| Nanjing Maternity and Child Health Care Hospital/Department of Breast Surgery | Nanjing | Jiangsu | China |
| Suzhou Municipal Hospital | Suzhou | Jiangsu | 215002 | China |
| The first hospital of jilin university | Changchun | Jilin | 130021 | China |
| The Fourth Affiliated Hospital Of China Medical University | Shenyang | Liaoning | 110032 | China |
| The First Affiliated Hospital of The Fourth Military Medical University | Xi'an | Shaanxi | 710032 | China |
| The First Affiliated Hospital of Xi'an Jiaotong University | Xi'an | Shaanxi | 710061 | China |
| Linyi People's Hospital | Linyi | Shandong | 276000 | China |
| The Affiliated Hospital of Qingdao University | Qingdao | Shandong | 266061 | China |
| Qingdao municipal Hospital | Qingdao | Shandong | 266072 | China |
| Breast Surgery of The Weifang People's Hospital | Weifang | Shandong | 261041 | China |
| Breast Surgery of YanTai Yu Huang Ding Hospital | Yantai | Shandong | 264000 | China |
| Breast and thyroid surgery of Central Hospital of Zibo | Zibo | Shandong | 255036 | China |
| West China Hospital, Sichuan University/ Oncology Department | Chengdu | Sichuan | 610041 | China |
| Sichuan Provincial People's Hospital | Chengdu | Sichuan | 610072 | China |
| Affiliated Hospital of North Sichuan Medical College | Nanchong | Sichuan | 637000 | China |
| Tianjin Cancer Hospital/Breast cancer department | Tianjin | Tianjin Municipality | 300060 | China |
| Affiliated Cancer Hospital of Xinjiang Medical University | Ürümqi | Xinjiang | 830000 | China |
| Yunnan Cancer Hospital | Kunming | Yunnan | 650118 | China |
| Zhejiang Cancer Hospital | Hangzhou | Zhejiang | 310022 | China |
| Cancer Hospital Chinese Academy of medical sciences | Beijing | 100021 | China |
| Fifth Medical Center of the PLA General Hospital | Beijing | 100071 | China |
| Beijing Cancer Hospital | Beijing | 100142 | China |
| Peking University Third Hospital/Department of Oncology | Beijing | 100191 | China |
| China-Japan Friendship Hospital | Beijing | China |
| Fudan University Shanghai Cancer center/Department of Breast Surgery | Shanghai | 200032 | China |
| Yangpu District Central Hospital | Shanghai | 200090 | China |
| Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine | Shanghai | 200092 | China |
| Treated |
|
| Assigne But Not Treated |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
Baseline analysis population included all participants who were treated.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Exemestane | Participants received exemestane (Aromasin) tablet 25 mg once daily in this study. They had previously taken tamoxifen for 2 to 3 years and switched to Aromisin in this study for completion of 5 consecutive years of adjuvant hormonal therapy. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Time-to-Event | An event was defined as the earliest occurrence of any of the following: 1) Loco-regional/distant recurrence of the primary breast cancer (BC) (Loco-regional recurrence was defined as any recurrence in the ipsilateral breast, chest wall or axillary lymph nodes.); 2) Appearance of a second primary or contralateral breast cancer; 3) Death due to any cause. | The full analysis set (FAS) was defined as all participants who received at least 1 dose of Aromasin during the observation period. All efficacy analyses were performed using the FAS. | Posted | Median | 95% Confidence Interval | months | 2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years) |
|
|
| |||||||||||||||||||||||||
| Secondary | Percentage of Participants Experiencing Each Event | An event was defined as the following: 1) Loco-regional/distant recurrence of the primary breast cancer (Loco-regional recurrence was defined as any recurrence in the ipsilateral breast, chest wall or axillary lymph nodes.); 2) Appearance of a second primary or contralateral breast cancer; 3) Death due to any cause. | The FAS was defined as all participants who received at least 1 dose of Aromasin during the observation period. All efficacy analyses were performed using the FAS. | Posted | Number | 95% Confidence Interval | percentage of participants | 2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years) |
|
| ||||||||||||||||||||||||||
| Secondary | Incidence Rate of Each Event | Incidence rate (per annum) of the event was defined as a ratio of the number of events and the total exposure time (in years) to Aromasin therapy. | The FAS was defined as all participants who received at least 1 dose of Aromasin during the observation period. All efficacy analyses were performed using the FAS. | Posted | Number | events per person-year | 2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years) |
|
| |||||||||||||||||||||||||||
| Secondary | Hazard Ratio: the Relationship Between (Human Epidermal Growth Factor Receptor 2) HER2 Status and Time-to-Event | A Cox proportional hazards regression model was used to evaluate the relationship between HER2 status level (binary) and time-to-event (Positive vs Negative). The method for selecting factors for the Cox regression model was based on significant results at univariate analysis and the clinical judgement for the multivariate model. Stepwise method was used for the selection of final independent variables. The criteria for stepwise selection were pentry = 0.25 and pstay = 0.15. | The FAS was defined as all participants who received at least 1 dose of Aromasin during the observation period. All efficacy analyses were performed using the FAS. | Posted | Number | 95% Confidence Interval | ratio | 2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years) |
|
| ||||||||||||||||||||||||||
| Secondary | Harzard Ratio: the Relationship Between Multiple Disease Variables and Time-to-Event | A Cox proportional hazards regression model with stepwise selection was used to evaluate the influence of multiple disease variables on the time-to-event. The disease variables in the initial model included Eastern Cooperative Oncology Group [ECOG] performance status at diagnosis; and Tumor, Lymph Node and Metastasis [TNM] stage at initial diagnosis. The ECOG Performance Status describes a patient's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability. ECOG performance status at diagnosis level included 0, 1, 2, 3 and 4, with Level 0 as the best status and Level 4 as the worst. The TNM system helps describe the size of cancer tumor and the extent to which it spreads to nearby tissues/distant parts of the body. TNM stage at initial diagnosis level included 1 (Stage I), 2 (Stage IIA), 3 (Stage IIB), 4 (Stage IIIA), 5 (Stage IIIB) and 6 (Stage IIIC), with Level 1 as the best status and Level 6 as the worst. | The FAS was defined as all participants who received at least 1 dose of Aromasin during the observation period. All efficacy analyses were performed using the FAS. | Posted | Number | 95% Confidence Interval | ratio | 2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years) |
| |||||||||||||||||||||||||||
| Secondary | Number of Participants With Discontinuation Due to Adverse Events (AEs) | Participants permanently discontinued from the study due to AEs were counted for this outcome measure. An AE is any untoward medical occurrence in a clinical investigation subject administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. The number of participants with discontinuation due to all-causality and treatment-related AEs are reported below. Treatment-related AEs were determined by the investigator. | The safety analysis set (SAS) was defined as all enrolled participants who took at least 1 dose of the study drug. All safety analyses were reported within the SAS. | Posted | Count of Participants | Participants | 2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years) |
|
| |||||||||||||||||||||||||||
| Secondary | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | All-causality TEAEs were counted for this outcome measure. TEAE is defined as an event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state. The number of participants with all-causality and treatment-related TEAEs are reported below. Treatment-related TEAEs were determined by the investigator. | The SAS was defined as all enrolled participants who took at least 1 dose of the study drug. All safety analyses were reported within the SAS. | Posted | Count of Participants | Participants | 2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years) |
|
|
2-3 years (time for previously taking tamoxifen [prior to this study] and time for taking Aromasin [in this study] add up to 5 years)
The same event may appear as both an AE and a SAE. An event may be categorized as serious in 1 participant and as non-serious in another participant, or 1 participant may have experienced both a serious and non-serious event during the study. Total number at risk below refers to the number of participants evaluable for SAEs or AEs.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Exemestane | Participants received exemestane (Aromasin) tablet 25 mg once daily in this study. They had previously taken tamoxifen for 2 to 3 years and switched to Aromisin in this study for completion of 5 consecutive years of adjuvant hormonal therapy. | 4 | 558 | 38 | 558 | 82 | 558 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Angina unstable | Cardiac disorders | MedDRA 21.1 | Non-systematic Assessment |
| |
| Coronary artery disease | Cardiac disorders | MedDRA 21.1 | Non-systematic Assessment |
| |
| Autoimmune thyroiditis | Endocrine disorders | MedDRA 21.1 | Non-systematic Assessment |
| |
| Goitre | Endocrine disorders | MedDRA 21.1 | Non-systematic Assessment |
| |
| Hypothyroidism | Endocrine disorders | MedDRA 21.1 | Non-systematic Assessment |
| |
| Glaucoma | Eye disorders | MedDRA 21.1 | Non-systematic Assessment |
| |
| Chronic gastritis | Gastrointestinal disorders | MedDRA 21.1 | Non-systematic Assessment |
| |
| Gastric polyps | Gastrointestinal disorders | MedDRA 21.1 | Non-systematic Assessment |
| |
| Haemorrhoids | Gastrointestinal disorders | MedDRA 21.1 | Non-systematic Assessment |
| |
| Tongue haemorrhage | Gastrointestinal disorders | MedDRA 21.1 | Non-systematic Assessment |
| |
| Chest pain | General disorders | MedDRA 21.1 | Non-systematic Assessment |
| |
| Death | General disorders | MedDRA 21.1 | Non-systematic Assessment |
| |
| Disease progression | General disorders | MedDRA 21.1 | Non-systematic Assessment |
| |
| Cholecystitis chronic | Hepatobiliary disorders | MedDRA 21.1 | Non-systematic Assessment |
| |
| Cholelithiasis | Hepatobiliary disorders | MedDRA 21.1 | Non-systematic Assessment |
| |
| Localised infection | Infections and infestations | MedDRA 21.1 | Non-systematic Assessment |
| |
| Lung infection | Infections and infestations | MedDRA 21.1 | Non-systematic Assessment |
| |
| Post procedural infection | Infections and infestations | MedDRA 21.1 | Non-systematic Assessment |
| |
| Upper respiratory tract infection | Infections and infestations | MedDRA 21.1 | Non-systematic Assessment |
| |
| Ankle fracture | Injury, poisoning and procedural complications | MedDRA 21.1 | Non-systematic Assessment |
| |
| Rib fracture | Injury, poisoning and procedural complications | MedDRA 21.1 | Non-systematic Assessment |
| |
| Scapula fracture | Injury, poisoning and procedural complications | MedDRA 21.1 | Non-systematic Assessment |
| |
| Type 2 diabetes mellitus | Metabolism and nutrition disorders | MedDRA 21.1 | Non-systematic Assessment |
| |
| Intervertebral disc protrusion | Musculoskeletal and connective tissue disorders | MedDRA 21.1 | Non-systematic Assessment |
| |
| Breast fibroma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 21.1 | Non-systematic Assessment |
| |
| Ewing's sarcoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 21.1 | Non-systematic Assessment |
| |
| Fibroadenoma of breast | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 21.1 | Non-systematic Assessment |
| |
| Papillary thyroid cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 21.1 | Non-systematic Assessment |
| |
| Thyroid adenoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 21.1 | Non-systematic Assessment |
| |
| Cerebral infarction | Nervous system disorders | MedDRA 21.1 | Non-systematic Assessment |
| |
| Post herpetic neuralgia | Nervous system disorders | MedDRA 21.1 | Non-systematic Assessment |
| |
| Renal cyst | Renal and urinary disorders | MedDRA 21.1 | Non-systematic Assessment |
| |
| Ureterolithiasis | Renal and urinary disorders | MedDRA 21.1 | Non-systematic Assessment |
| |
| Breast calcifications | Reproductive system and breast disorders | MedDRA 21.1 | Non-systematic Assessment |
| |
| Uterine polyp | Reproductive system and breast disorders | MedDRA 21.1 | Non-systematic Assessment |
| |
| Hypertension | Vascular disorders | MedDRA 21.1 | Non-systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA 21.1 | Non-systematic Assessment |
| |
| Vaginal haemorrhage | Reproductive system and breast disorders | MedDRA 21.1 | Non-systematic Assessment |
|
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Pfizer ClinicalTrials.gov Call Center | Pfizer, Inc. | 1-800-718-1021 | ClinicalTrials.gov_Inquiries@pfizer.com |
| Prot_001.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Jun 21, 2015 | Nov 26, 2019 | SAP_000.pdf |
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C056516 | exemestane |
Not provided
Not provided
Not provided
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
|
|
|
|
|
|
|